Market Research Report
Canada Breast Cancer Diagnostics Market 2019-2025
|Canada Breast Cancer Diagnostics Market 2019-2025|
Published: February 21, 2020
Orion Market Research Pvt Ltd
Delivery time: 2-3 business days
Canada Breast Cancer Diagnostics Market Size, Share & Trends Analysis Report by Technology (Mammography, Biopsy, PET/CET, Ultrasound, and Others), By End-User (Hospitals and Diagnostic Centers) and Forecast 2019-2025
Canada breast cancer diagnostics market is estimated to grow significantly at a CAGR of around 11.5% during the forecast period. The factors that influence the market growth in Canada include increasing the screening test for breast cancer and prevalence due to changes in life style. Breast cancer is the second leading cause of mortality in Canada. The incidence rate of breast cancer in Canada slightly increase with the increase in years. According to the Canadian Cancer Society about 26,300 women diagnosed with breast cancer in 2017. This accounts for 25% of all new cancer cases in women. The mortality due to breast cancer was about 5,000, which is 13% of all cancer mortality in women. On average 72 women in Canada were diagnosed and 14 women died with breast cancer every day. The breast cancer also happened in men about 230 men were diagnosed and mortality about 60 from breast cancer in 2017.
Canada breast cancer diagnostics market is segmented on the basis of technology. Based on technology, the market is further classified into mammography, biopsy, position emission tomography/Computed tomography, ultrasound, and others. The mammography segment is projected to hold the largest share in the market. Mammography is a specific medical imaging technique that uses a low-dose x-ray system to see inside the breasts. A mammography exam, called a mammogram, aids in the early detection and diagnosis of breast diseases in women. The end-user segment market is further segregated into hospitals and diagnostics centers.
The companies which are contributing to the growth of the Canada breast cancer diagnostics market include Agendia NV, Becton, Dickinson and Co., Danaher Corp., General Electric Co., Hologic Inc., Johnson & Johnson Services Inc., Myriad Genetics, Inc., NanoString Technologies, Inc., Koninklijke Philips N.V., Siemens Healthcare GmbH, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market.
The market study of the Canada breast cancer diagnostics market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.
Secondary Sources Include
The Report Covers: